| scholarly article | Q13442814 |
| P50 | author | Karl Y Hostetler | Q56642709 |
| P2093 | author name string | Earl R Kern | |
| James R Beadle | |||
| W Brad Wan | |||
| Deborah J Bidanset | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 499-503 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection | |
| P478 | volume | 190 |
| Q34464655 | Acyclic nucleoside phosphonates: a key class of antiviral drugs |
| Q37401749 | Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. |
| Q57171792 | Antiviral Therapies for Herpesviruses: Current Agents and New Directions |
| Q24672068 | Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy |
| Q40469465 | Brincidofovir Is Not A Substrate For The Human Organic Anion Transporter 1 (Oat1): A Mechanistic Explanation For The Lack Of Nephrotoxicity Observed In Clinical Studies. |
| Q37420102 | Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies |
| Q37700176 | CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency |
| Q35270714 | CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections |
| Q38614278 | Cidofovir Activity against Poxvirus Infections |
| Q33935329 | Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro |
| Q33804593 | Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro |
| Q33351523 | Cytomegalovirus: pathogen, paradigm, and puzzle |
| Q41862474 | Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models. |
| Q24629979 | Efficacy of CMX001 against Herpes Simplex Virus Infections in Mice and Correlations with Drug Distribution Studies |
| Q34027426 | Emerging drugs for varicella-zoster virus infections |
| Q43261185 | Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. |
| Q36095046 | Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections |
| Q36734750 | Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model |
| Q38007145 | Highlights in antiviral drug research: antivirals at the horizon |
| Q37967568 | Human cytomegalovirus infection and atherothrombosis |
| Q24556634 | Human cytomegalovirus resistance to antiviral drugs |
| Q55385252 | Inflammation and outer blood-retina barrier (BRB) compromise following choroidal murine cytomegalovirus (MCMV) infections. |
| Q37450711 | Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides |
| Q39929713 | Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates. |
| Q36233543 | Main adult herpes virus infections of the CNS. |
| Q37624896 | Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections |
| Q34483696 | Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection |
| Q37488882 | Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir |
| Q38005228 | Prodrug strategies in ocular drug delivery |
| Q35590695 | Progress in the development of new therapies for herpesvirus infections |
| Q34149904 | Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management |
| Q36969798 | Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus |
| Q36950587 | Synthesis and antiviral activity of 6-deoxycyclopropavir, a new prodrug of cyclopropavir. |
| Q40157684 | Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir. |
| Q42738365 | Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir |
| Q35013420 | Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine |
| Q38280949 | The development of new therapies for human herpesvirus 6. |
| Q37173390 | The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis |
| Q37811458 | The search for new therapies for human cytomegalovirus infections. |
| Q40426465 | Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients |
| Q36185647 | Update on New Antivirals Under Development for the Treatment of Double-Stranded DNA Virus Infections |
Search more.